Zoetis Inc. (ZTS) is a renowned global leader in the animal health industry. Incorporated in 1952 and headquartered in Parsippany, New Jersey, United States, the company has a prominent presence around the globe, offering its products and services in approximately 100 countries.
Zoetis is committed to innovating and serving veterinarians, livestock producers, pet owners, and other animal health professionals. The company's comprehensive portfolio comprises over 300 product lines, covering eight core animal species, including dogs, cats, horses, cattle, swine, poultry, sheep, and fish. Zoetis is known for developing, manufacturing, and commercializing an impressive range of veterinary medicines, vaccines, diagnostic products, genetic tests, biodevices, and a variety of services.
The portfolio includes popular products like Apoquel and Cytopoint for treating allergic dermatitis in dogs, and Draxxin, a leading antibiotic for livestock. Additionally, Zoetis has launched innovative diagnostic products like the WITNESS line of rapid diagnostic tests and ClariFly, a feed supplement to prevent flies in livestock environments.
Zoetis is committed to advancing animal health and well-being worldwide. They continually invest in research and development in anticipation of the evolving needs of animal health. This unrelenting focus on innovation and cutting-edge technology has positioned Zoetis as a frontrunner in their field, enabling them to provide valuable solutions to the widest possible community of customers.
In the financial perspective, Zoetis has been consistently delivering strong performance. The company has been listed on the New York Stock Exchange (NYSE) since 2013 under the ticket name "ZTS". It has progressively grown its shareholder returns, thanks to its robust financials and future-oriented strategy.
Moreover, the company's commitment to corporate responsibility is commendable. Zoetis takes a holistic approach in its operations, taking into account environmental preservation, animal well-being, employee safety, product quality, and corporate governance.
Overall, Zoetis has a rich heritage and a bright future in global animal health, standing as a pillar of industry expertise and customer service. With the drive for continuous growth and commitment to breaking new grounds in animal health, Zoetis is set for remarkable innovations and breakthroughs in the field.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Eleven ratings firms have given Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) a "Reduce" recommendation, with an average 12-month price target of $23.57. Despite this cautious sentiment, the company reported stronger-than-expected quarterly results, with adjusted earnings of $0.66 per share and revenue of $5.55 billion. Institutional ownership of FMS stock has increased, although collective institutional holdings remain at 8.37%.
Veeco Instruments (NASDAQ:VECO) has received a consensus "Hold" rating from Wall Street analysts, with an average 12-month price target of $61.33, significantly above its current trading price of $45.45. The company recently surpassed quarterly earnings expectations, reporting $0.33 EPS and $193.48 million in revenue. Despite strong institutional ownership, recent insider sales by the CEO and CFO have been noted.
The GAMCO Natural Resources, Gold & Income Trust (GNT) Q2 2026 commentary highlights significant market declines in gold bullion, crude oil, and agribusiness, with gold down 14.1% and crude oil down 31.4%. GNT responded by increasing its cash position to 24% and maintaining diversified sector allocations across gold/base metals, agriculture, and energy to manage volatility. The fund also increased its monthly distribution to $0.06 and continued its covered call strategy to generate income despite market turmoil.
Andra AP fonden significantly increased its stake in Ameriprise Financial, Inc. (NYSE:AMP) during the second quarter, purchasing 62,718 additional shares and bringing its total holdings to 70,518 shares valued at approximately $32.4 million. Despite the firm exceeding quarterly earnings and revenue expectations, Ameriprise shares recently fell 4.5% to $511.45. Analyst sentiment remains generally positive, with the stock holding a "Moderate Buy" consensus rating and an average price target of $555.33.
Wall Street Zen has upgraded Grifols (NASDAQ:GRFS) from a "hold" to a "buy" rating, despite a broader analyst consensus of "Reduce." The company's shares opened at $7.31, close to its 52-week low, with a market capitalization of $4.98 billion. Several institutional investors, including Tidal Investments and Hennion & Walsh Asset Management, have recently increased their holdings in Grifols.
IDEXX Laboratories (IDXX) stock has significantly underperformed the Dow Jones Industrial Average over the past year and in 2026, with shares down 23.9% year-to-date and 21.4% over 52 weeks, compared to the Dow's positive returns. Despite this, the company showed improving momentum in Q2, with strong revenue and EPS growth, and analysts maintain a "Moderate Buy" rating with a substantial price target premium. The underperformance is attributed to investor concerns about slower veterinary clinic traffic, though recent results suggest a recovery.
DAQO New Energy Corp. (NYSE:DQ) has received a consensus "Reduce" rating from seven brokerages, with an average 12-month price target of $19.36. The company's shares opened at $12.49, near its one-year low, and it reported a quarterly loss of $1.20 per share, missing analyst expectations despite exceeding revenue estimates. Several analysts have recently lowered their ratings or price targets for the stock.
Gilead Sciences CEO Daniel Patrick O'Day sold 15,000 shares of company stock for $2.23 million on September 1st, under a pre-arranged Rule 10b5-1 plan. This sale reduced his position by 2.53%, leaving him with 577,133 shares. The transaction follows previous sales in August and July and comes as Gilead reported strong Q2 revenue of $7.80 billion, exceeding analyst estimates, and announced a quarterly dividend of $0.82 per share.